

## Datasheet: PIP023

|                      |                               |
|----------------------|-------------------------------|
| <b>Description:</b>  | NATIVE VARICELLA ZOSTER VIRUS |
| <b>Name:</b>         | VARICELLA ZOSTER VIRUS        |
| <b>Other names:</b>  | VZV                           |
| <b>Format:</b>       | Inactivated Pathogen          |
| <b>Product Type:</b> | Antigen                       |
| <b>Quantity:</b>     | 1 ml                          |

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

|       | Yes | No | Not Determined | Suggested Dilution |
|-------|-----|----|----------------|--------------------|
| ELISA | ▪   |    |                |                    |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

|                                       |   |
|---------------------------------------|---|
| <b>Target Species</b>                 | Viral   |
| <b>Product Form</b>                   | Inactivated Varicella zoster virus  |
| <b>Preparation</b>                    | Varicella zoster virus, VZ-10 strain, cultured in MRC-5 cells. Optimally infected monolayers are harvested, resuspended in a small volume of tissue culture fluid and disrupted by sonication. The suspension is subjected to low speed centrifugation and the resulting supernatant constitutes the antigen preparation. The antigen preparation is inactivated using gamma radiation, which primarily damages viral genetic material. |
| <b>Buffer Solution</b>                | Eagle's Minimum Essential Medium (MEM)  |
| <b>Preservative Stabilisers</b>       | None present  |
| <b>Approx. Protein Concentrations</b> | Current, batch-specific concentration 2.3 mg/ml   |
| <b>Product Information</b>            | <b>Native Varicella zoster Virus preparation</b> contains a high concentration of virus and viral components as well as some cellular material suspended in EMEM with some serum  |

proteins.

Varicella zoster virus is a member of the herpesvirus family. It commonly causes chickenpox in children and shingles and postherpetic neuralgia in adults. Chickenpox is a common childhood disease characterised by a vesicular skin rash, becoming itchy pockmarks which eventually heal, mostly without scarring. The disease has a 10-21 day incubation period and is easily spread through coughs and sneezes or direct contact with secretions from the rash. The disease is rare, but generally more serious, in adults. The primary outbreak usually confers lifelong protective immunity, however, the virus can go on to cause shingles, a completely different disease, many years after a chickenpox outbreak. Shingles is characterised by a painful skin rash in a limited area on the body. The rash normally heals within two to four weeks, but some individuals may suffer from postherpetic neuralgia, or nerve pain, for months or years to follow.

---

**Activity** Antigenic activity is 158% of internal reference standard.

---

**Instructions For Use** PIP023 should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats or may be further purified to meet the requirements of a particular assay format.

---

**Storage** Store at -70°C.  
Storage in frost-free freezers is not recommended.  
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.

---

**Guarantee** 12 months from date of despatch

---

**Health And Safety Information** Material Safety Datasheet documentation #10286 available at:  
10286: <https://www.bio-rad-antibodies.com/uploads/MSDS/10286.pdf>

This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately.

---

**Regulatory** For research purposes only

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M390463:210913'

**Printed on 21 Mar 2022**

---

© 2022 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)